DUBLIN — The “Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028” report has been added to ResearchAndMarkets.com’s offering. The global multiple myeloma drugs market has experienced substantial growth, achieving a noteworthy US$ 21.0 Billion in 2022. Projections by industry experts indicate continued expansion, with the...
Latest News
CHAPEL HILL, North Carolina – At all dose levels, revumenib (Revuforj) plus azacitidine (Vidaza) and venetoclax (Venclexta) showed safety and feasibility for patients who are newly diagnosed and older with acute myeloid leukemia (AML) harboring NPM1 mutations or KMT2A rearrangement (KMT2Ar), according to findings from the phase 3 VIALE-A trial (NCT02993523) presented at...
Independent Data Monitoring Committee (the “DMC”) recommends continuation of sunRIZE trial as planned with no need to increase sample size Enrollment on track and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. sites activated and enrolling patients REDWOOD CITY, Calif. — Rezolute, Inc. (Nasdaq:...
REDWOOD CITY, Calif. — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the completion of enrollment in its RZ402 Phase 2 study in diabetic macular edema (“DME”). RZ402 is a selective and potent plasma kallikrein inhibitor (“PKI”) being developed...
REDWOOD CITY, Calif. — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today shared observations from the Phase 3 sunRIZE study in patients with congenital HI and provided details on the treatment of tumor HI...
REDWOOD CITY, Calif. — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced outcomes from an in-person Type B meeting with the U.S. Food and Drug Administration (FDA) held on March 17, 2026, related to sunRIZE, a Phase 3,...
LOUISVILLE, Ky. – Onco360®, the nation’s largest independent Oncology Pharmacy, has been selected by Kadmon Pharmaceuticals, LLC to be a specialty pharmacy partner for REZUROCK (belumosudil), a new oral treatment for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure...
WOBURN, Mass. — Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RGT-61159 for the...
Data are being presented at the 30th Annual Congress of the European Hematology Association 2025 (EHA2025) WOBURN, Mass. — Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, announced today the presentation...
WOBURN, Mass. — Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, announced today that preclinical data from its new Huntington’s disease (HD) drug candidate targeting PMS1, RGT-0474060, were presented at the...